DUBLIN, August 10, 2010 /PRNewswire-FirstCall/ -- Shire plc
(LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical
company, announced the divestiture of Daytrana(R) (methylphenidate
transdermal system) to Noven Pharmaceuticals, Inc. Daytrana, which
is approved and marketed in the US for the treatment of Attention
Deficit Hyperactivity Disorder (ADHD) in children and adolescents,
will continue to be available for patients through Noven.

Shire's divestiture agreement grants Noven global marketing
rights for Daytrana and is effective October 1, 2010. The book
value of the assets to be disposed is approximately $95 million (or
a gross, pre-amortization value of approximately $150 million).
Shire's 2010 outlook of Non GAAP earnings trending towards $4.00
per ADS which was recently announced in its second quarter earnings
press release is unchanged.

Noven developed and manufactures Daytrana, and Noven licensed
Daytrana to Shire in 2003. The US Food and Drug Administration
(FDA) approved Daytrana as a treatment for ADHD in children and
adolescents in April 2006 and June 2010, respectively.

Indication

Daytrana is a prescription central nervous system (brain)
stimulant medicine used to treat ADHD in people 6 to 17 years old.
Daytrana may help increase attention and decrease impulsive and
hyperactive behavior. Daytrana should be used as a part of a total
treatment program for ADHD that may include counseling or other
therapies.

Important Safety Information

IMPORTANT:

Daytrana is a controlled substance (CII) because it can be
abused or lead to dependence. Keep Daytrana in a safe place to
protect it from theft. Selling or giving away Daytrana may harm
others and is against the law.

Tell the prescribing doctor if your child has ever abused or
been dependent on alcohol, prescription medicines or street
drugs.

Daytrana should not be used if your child is very anxious,
tense, or agitated; has an eye problem called glaucoma; has tics
(repeated movements or sounds that cannot be controlled) has a
diagnosis or family history of seizures or has a diagnosis or
family history of Tourette's syndrome; or have had an abnormal
brain wave test (EEG); is taking a monoamine oxidase inhibitor
(MAOI) medicine or has discontinued an MAOI medicine in the last 2
weeks; is pregnant or breastfeeding; is allergic to methylphenidate
or any other ingredients of Daytrana.

Serious heart problems have been reported with Daytrana or other
stimulant medicines including:

- sudden death in people with heart problems or heart
defects
- stroke and heart attack in adults
- increased blood pressure and heart rate

Tell the doctor if your child or a family member has any heart
problems, heart defects, or increased blood pressure and heart
rate. Remove the Daytrana patch and call the doctor right away if
your child has any signs of heart problems such as chest pain,
shortness of breath, or fainting while using Daytrana.

Serious mental (psychiatric) problems have been reported with
Daytrana or other stimulant medicines including:

- new or worse aggressive behavior, hostility, anger or
irritability
- new or worse bipolar illness or mania (an extreme increase
in
activity or talking)
- new or worse psychosis (hearing or seeing things that are
not
real, being suspicious, or distrustful, believing things that are
not
true)
- other unusual or extreme changes in behavior or mood

Tell the doctor about any mental problems your child or family
members have including suicide or depression, bipolar illness,
mania, or psychosis. Call the doctor right away if your child has
any new or worsening mental symptoms or problems while using
Daytrana.

Serious side effects such as seizures (this usually happens in
people with a history of seizures), slowing of growth (weight and
height), eyesight changes or blurred vision have been reported with
Daytrana. Allergic skin rash may occur. Stop using Daytrana and see
the doctor right away if swelling, bumps, or blisters happen at or
around where the patch is applied.

If the patch is worn longer than 9 hours in a day, or if more
than 1 patch is worn at a time, too much Daytrana has been used.
Your child should not use hair dryers, heating pads, electric
blankets, heated water beds or other heat sources while wearing a
Daytrana patch. This could cause too much medicine to pass into
your child's body and cause serious side effects.

Your child should have his or her height and weight checked
often while taking Daytrana and your doctor may stop treatment if a
problem is found during these check-ups.

Most common side effects seen with Daytrana include skin
problems (redness, small bumps, itching) where the patch is
applied, poor appetite, nausea, vomiting, stomach pain, weight
loss, tics, trouble sleeping, mood swings, and dizziness.

You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit http://www.FDA.gov/medwatch or
call 1-800-FDA-1088.

About ADHD

ADHD is one of the most common psychiatric disorders in children
and adolescents. Worldwide prevalence of ADHD is estimated at 5.3
percent (with large variability), according to a comprehensive
systematic review of this topic published in 2007 in the American
Journal of Psychiatry. In the United States, approximately 7.8
percent of all school-aged children, or about 4.4 million children
aged 4 to 17 years, have been diagnosed with ADHD at some point in
their lives, according to the Centers for Disease Control and
Prevention (CDC).

ADHD is a psychiatric behavioral disorder that manifests as a
persistent pattern of inattention and/or hyperactivity-impulsivity
that is more frequent and severe than is typically observed in
individuals at a comparable level of development. The specific
etiology of ADHD is unknown and there is no single diagnostic test
for this disorder. Adequate diagnosis requires the use of medical
and special psychological, educational and social resources,
utilizing diagnostic criteria such as Diagnostic and Statistical
Manual of Mental Disorders-IV (DSM-IV(R)) or International
Classification of Diseases 10 (ICD-10).

Although there is no cure for ADHD, there are accepted
treatments that specifically target its symptoms. Standard
treatments include educational approaches, psychological or
behavioral modification, and/or medication.

SHIRE PLC

Shire's strategic goal is to become the leading specialty
biopharmaceutical company that focuses on meeting the needs of the
specialist physician. Shire focuses its business on attention
deficit hyperactivity disorder (ADHD), human genetic therapies
(HGT) and gastrointestinal (GI) diseases as well as opportunities
in other therapeutic areas to the extent they arise through
acquisitions. Shire's in-licensing, merger and acquisition efforts
are focused on products in specialist markets with strong
intellectual property protection and global rights. Shire believes
that a carefully selected and balanced portfolio of products with
strategically aligned and relatively small-scale sales forces will
deliver strong results.

For further information on Shire, please visit the Company's
website: http://www.shire.com.

Statements included herein that are not historical facts are
forward-looking statements. Such forward-looking statements involve
a number of risks and uncertainties and are subject to change at
any time. In the event such risks or uncertainties materialize, the
Company's results could be materially adversely affected. The risks
and uncertainties include, but are not limited to, risks associated
with: the inherent uncertainty of research, development, approval,
reimbursement, manufacturing and commercialization of the Company's
Specialty Pharmaceutical and Human Genetic Therapies products, as
well as the ability to secure and integrate new products for
commercialization and/or development; government regulation of the
Company's products; the Company's ability to manufacture its
products in sufficient quantities to meet demand; the impact of
competitive therapies on the Company's products; the Company's
ability to register, maintain and enforce patents and other
intellectual property rights relating to its products; the
Company's ability to obtain and maintain government and other
third-party reimbursement for its products; and other risks and
uncertainties detailed from time to time in the Company's filings
with the Securities and Exchange Commission.